Introduction: To evaluate the safety profile characteristics of abiraterone acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas covered: In this literature review the authors evaluate safety data from phase III trials investigating the combination of abiraterone acetate plus prednisone (AAP) in patients with metastatic prostate cancer. In particular, the aim was to clarify its toxicity profile, long-term exposure impact, and the correlation with general health-related quality of life (HRQoL). Expert opinion: Based on the studies reviewed, it appears that abiraterone acetate has favourable outcomes, is effective and well tolerated, mostly in asymptomatic or slightly symptomatic patients, and has recognised toxicity profile characteristics. Incidence of adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, and hepatotoxicity is well known and widely described. Understanding the toxicity profile of AA could assist decision-making in clinical practice.

A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer / Castellan, P.; Castellucci, R.; Marchioni, M.; De Nunzio, C.; Tema, G.; Primiceri, G.; Schips, L.; Cindolo, L.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 18:9(2019), pp. 759-767. [10.1080/14740338.2019.1648428]

A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer

Marchioni M.;De Nunzio C.;Tema G.;Primiceri G.;
2019

Abstract

Introduction: To evaluate the safety profile characteristics of abiraterone acetate (AA) in the treatment of metastatic prostate cancer (mPCa). Areas covered: In this literature review the authors evaluate safety data from phase III trials investigating the combination of abiraterone acetate plus prednisone (AAP) in patients with metastatic prostate cancer. In particular, the aim was to clarify its toxicity profile, long-term exposure impact, and the correlation with general health-related quality of life (HRQoL). Expert opinion: Based on the studies reviewed, it appears that abiraterone acetate has favourable outcomes, is effective and well tolerated, mostly in asymptomatic or slightly symptomatic patients, and has recognised toxicity profile characteristics. Incidence of adverse events (AEs), such as mineralocorticoid- and corticosteroid-releated AEs, and hepatotoxicity is well known and widely described. Understanding the toxicity profile of AA could assist decision-making in clinical practice.
2019
abiraterone acetate; androgen receptor; castration-resistant prostate cancer; hormone-naïve prostate cancer; metastatic prostate cancer; toxicity
01 Pubblicazione su rivista::01a Articolo in rivista
A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer / Castellan, P.; Castellucci, R.; Marchioni, M.; De Nunzio, C.; Tema, G.; Primiceri, G.; Schips, L.; Cindolo, L.. - In: EXPERT OPINION ON DRUG SAFETY. - ISSN 1474-0338. - 18:9(2019), pp. 759-767. [10.1080/14740338.2019.1648428]
File allegati a questo prodotto
File Dimensione Formato  
Castellan_A drug safety_2019.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1456546
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact